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Paroxysmal exercise-induced dyskinesia (PED) can occur in isolation or in association with epilepsy, but the
genetic causes and pathophysiological mechanisms are still poorly understood.We performed a clinical evalua-
tion and genetic analysis in a five-generation family with co-occurrence of PED and epilepsy (n=39 ) ,s u gges t i ng
thatthis combination represents a clinical entity.Based on awhole genome linkage analysis we screened SLC2A1,
encoding the glucose transporter of the blood-brain-barrier, GLUT1 and identified heterozygous missense and
frameshift mutations segregating in this and three other nuclear families with a similar phenotype. PED was
characterized by choreoathetosis, dystonia or both, affecting mainly the legs. Predominant epileptic seizure
types were primary generalized. A median CSF/blood glucose ratio of 0.52 (normal `0.60) in the patients and
a reduced glucose uptake by mutated transporters compared with the wild-type as determined in Xenopus
oocytes confirmed a pathogenic role of these mutations. Functional imaging studies implicated alterations in
glucose metabolism in the corticostriate pathways in the pathophysiology of PED and in the frontal lobe
cortex in the pathophysiology of epileptic seizures. Three patients were successfully treated with a ketogenic
diet. In conclusion, co-occurring PED and epilepsy can be due to autosomal dominant heterozygous SLC2A1
mutations, expanding the phenotypic spectrum associated with GLUT1 deficiency and providing a potential
new treatment option for this clinical syndrome.
Keywords: GLUT1; paroxysmal dyskinesia; exercise-induced; GLUT1 deficiency syndrome; ketogenic diet
Abbreviations: AED = antiepileptic drugs; FDG = 2-[
18F]Fluoro-2-deoxy-D-glucose; GLUT1=facilitative glucose
transporter type 1; GLUT1 DS=GLUT1 deficiency syndrome; LOD=logarithms of odds; MNI=Montreal Neurological
Institute; OMG=3-O-methyl-D-glucose; PED=paroxysmal exercise-induced dyskinesias; PHD=paroxysmal hypnogenic
dyskinesias; PKD=paroxysmal kinesigenic dyskinesias; PNKD=paroxysmal non-kinesigenic dyskinesias; SPM=statistical
parametric mapping
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Paroxysmal dyskinesias are characterized by transient
abnormal, involuntary movement, such as choreoathetosis
and dystonia, but unlike the epilepsies they do not evolve
into tonic–clonic seizures, and are not associated with epi-
leptiform discharges and alterations in consciousness
(Berkovic, 2000). Broadly, the paroxysmal dyskinesias can
be subdivided into four subgroups based upon precipitating
factors: paroxysmal kinesigenic dyskinesia (PKD), parox-
ysmal non-kinesigenic dyskinesia (PNKD), paroxysmal
exercise-induced dyskinesia (PED) and paroxysmal hypno-
genic dyskinesia (PHD) (Demirkiran and Jankovic, 1995).
The association between paroxysmal dyskinesias and other
neurological disorders, like epilepsy or ataxia, has occa-
sionally been observed within one individual or family
(Jankovic and Demirkiran, 2001).
Molecular genetic analyses of multiplex families resulted
in the identification of a few loci and lent further support
to the hypothesis of a common genetic cause for parox-
ysmal dyskinesia/epilepsy/ataxia. Pure PKD was mapped to
the peri-centromeric region of chromosome 16 (Kato et al.,
2006), but the causative gene is unknown (Kikuchi et al.,
2007); several families with infantile convulsions and PKD
(Szepetowski et al., 1997; Lee et al., 1998; Swoboda et al.,
2000; Kato et al., 2006) and a family with autosomal
recessive rolandic epilepsy, PED and writer’s cramp also
map to the same chromosome 16 region (Guerrini et al.,
1999); pure PNKD maps to chromosome 2q33–q35, and
the myofibrillogenesis regulator 1 (MR-1) gene was identif-
ied as causative (Rainier et al., 2004). A family with
paroxysmal dyskinesia/ataxia precipitated by exercise, emo-
tional stress, sleep deprivation and alcohol consumption
was mapped to chromosome 1p (Auburger et al., 1996).
A family with PNKD and generalized epilepsy mapped
to chromosome 10q22, in which the a-subunit of a
calcium-sensitive potassium channel (KCNMA1) is mutated
(Du et al., 2005). A third defective gene, the MCT8 gene, is
known to cause an X-linked form of PKD with severe
global retardation (Brockmann et al., 2005).
PED is a rare form of paroxysmal dyskinesia with
approximately 20 sporadic patients and 9 PED families
reported (Lance, 1977; Plant et al., 1984; Nardocci et al.,
1989; Wali, 1992; Demirkiran and Jankovic, 1995; Auburger
et al., 1996; Bhatia et al., 1997; Kluge et al., 1998; Neville
et al., 1998; Guerrini et al., 1999, 2002; Nagamitsu et al.,
1999; Margari et al., 2000; Munchau et al., 2000; Bing et al.,
2005; Kamm et al., 2007). The co-occurrence of PED and
epilepsy has been occasionally noted (Plant et al., 1984;
Bhatia et al., 1997; Neville et al., 1998; Guerrini et al., 1999,
2002; Margari et al., 2000; Munchau et al., 2000; Bing et al.,
2005; Kamm et al., 2007). Here, we describe the clinical,
biochemical, imaging, electrophysiological and therapeutic
aspects of a syndrome characterized by co-occurring PED
and epilepsy. We elucidate its molecular pathophysiology
consisting of a decreased transport of glucose across the
blood-brain-barrier (BBB) due to mutations in the facil-
itative glucose transporter type 1 (GLUT1).
Material and Methods
Ascertainment and determination of phenotypes
We identified 56 members of a five-generation Belgian family
(family A) with PED and epilepsy (Fig. 1). Thirty-nine family
members participated in the genetic study. We interviewed and
Fig.1 Pedigree of families A^D. +=normal allele; m=mutated allele.Individuals carrying a heterozygous mutation in SLC2A1are indicated
with +/m. Individuals indicated with +/+ do not carry a mutated allele. Individuals without indication were not available for screening.
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For the other three individuals (II.2, III.4 and III.21), also carrying
a mutation, we only obtained clinical information from their
relatives and medical reports, when available. Three unrelated
nuclear families of Belgian (families B and C) and Ashkenazi
Jewish ancestry (family D), were subsequently evaluated. Available
interictal and ictal EEGs, and video-EEG recordings were
reviewed. Patients were diagnosed with epilepsy when experiencing
recurrent generalized tonic–clonic, absences, myoclonic (D.01) or
complex partial seizures. We also reviewed available brain MRI
scans, and performed 4- to 8-h-fasting serum glucose and cerebro-
spinal fluid (CSF) glucose concentration studies. We used the
following scale to score frequency of PED and epileptic seizures:
5: daily, 4: weekly, 3: monthly, 2: yearly, 1: remission 41 year,
0: no history of epilepsy or PED. The ethical committees of
University Hospital Gasthuisberg and University of Antwerp
approved this study and a written informed consent was obtained
from all participants or their legal representative.
Linkage analysis
Thirty-nine family members from family A were genotyped using
an in-house genome-wide mapping panel containing 425 auto-
somal microsatellite markers with an average marker distance of
7.8cM and a maximum marker distance of 15.3cM. Genetic
analyses were performed as described elsewhere (Deprez et al.,
2007). Additional markers in the candidate region between
D1S233 and D1S405 were selected from the Marshfield compre-
hensive genetic map (http://research.marshfieldclinic.org/genetics/)
and the ABI Prism Linkage Mapping Set MD-10 and MD-5
(Applied Biosystems, Foster City, CA, USA) for the fine mapping
of the region.
Two-point logarithms of odds (LOD) scores were calculated
using MLINK from the FASTLINK computer package (version 5.1)
(Cottingham et al., 1993). The affected status of individuals
was defined before linkage analysis. All patients with PED and/or
epilepsy were considered affected. LOD-scores were calculated
under the assumption of a dominant inheritance pattern with 95%
penetrance and a disease gene frequency of 0.001. The estimation
of the penetrance of the epileptic trait was based on the pedigree
of the entire family. For each marker, the number of alleles was set
at the observed number of alleles in the pedigree and we assumed
these alleles to be equifrequent.
Mutation analysis
Mutation analysis of all exons and intron–exon boundaries of
SLC2A1 was performed on genomic DNA of eight family members
of family A and all available members of families B–D by PCR
sequencing. Purified PCR products were subsequently sequenced
using the ABI BigDye Terminator cycle sequencing kit v3.1 and
analysed on an ABI 3730 automated sequencer (PE Applied
Biosystems, Foster City, CA, www.appliedbiosystems.com). Auto-
mated variation (SNPs and indels) discovery was performed using
novoSNP (Weckx et al., 2005). Subsequently, we used pyrose-
quencing (Alderborn et al., 2000) to confirm the presence of the
mutation in all patients and to exclude it in non-affected family
members and a panel of 184 ethnically matched control
individuals.
Functional analysis
The cDNA of SLC2A1 in the expression vector pSP65 was kindly
provided by Dr Mike Mueckler (Mueckler et al., 1985). The
QuickChange site-directed mutagenesis kit (Stratagene, LaJolla,
Canada) was used to introduce the three missense mutations into
the SLC2A1 cDNA, resulting in p.S95I, p.V140M, p.N317T amino
acid exchanges, respectively. Primer sequences are available upon
request. All mutations were verified by direct sequencing.
All further procedures about the expression and functional
characterization of the mutations compared with wild-type (WT)
transporters in Xenopus oocytes, including the preparation of
cRNA and oocytes, glucose uptake measurements in form of zero-
trans influx experiments with 3-O-methyl-D-glucose, kinetic
analysis to obtain Km and Vmax, Western blots and immuno-
cytochemistry to study protein stability and surface expression, as
well as Rb
+ flux experiments are described in detail elsewhere
(Weber et al., 2008). For the glucose uptake and Rb
+ flux studies,
three experiments using 10 oocytes each for every glucose
concentration (eight for Rb
+) were averaged for both mutant
and WT transporters on each experimental day. The procedures
for all four clones were done in parallel.
Functional imaging studies
Subjects
Fourteen patients with PED and epilepsy [8F, 6M; median age:
25 years (range: 13–52)] carrying a GLUT1 mutation were
investigated using 2-[
18F]Fluoro-2-deoxy-D-glucose (FDG) PET.
The metabolic results for the patient group were compared with
FDG PET data from 20 age- and sex-matched healthy volunteers
(11F, 9M; age range 21–49 years) that were obtained using the
same acquisition protocol and scanner. The healthy volunteers had
no history of neurological or psychiatric disorders and had normal
findings on T1- and T2-weighted brain MRI. The patients had CSF
and serum glucose studies immediately after the FDG PET scan,
but not the control subjects.
PET
PET metabolic data acquisition was performed according to the
standard clinical protocol (Van Laere et al., 2006). FDG data were
spatially normalized to Montreal Neurological Institute (MNI)
space using statistical parametric mapping (SPM) (version 2;
Wellcome Department of Imaging Neuroscience) with the stan-
dard settings. Normalized data were smoothed with an isotropic
Gaussian kernel of 10mm. A voxel-based group comparison of
patient group versus controls was performed after proportional
scaling the images (to compare the relative FDG uptake) and an
initial statistical threshold puncorrected 50.001 for peak height was
used. Only clusters with a corrected pcluster50.05 were considered
significant. Furthermore, voxel-based correlations were evaluated
between relative FDG uptake and CSF glucose, CSF/blood glucose
ratio and age in the patient group and epileptic seizure frequency
score and PED frequency score at time of FDG PET scanning in
the patient and control group combined.
One patient had an ictal SPECT scan during a PED episode.
We described the methodology of ictal SPECT previously (Dupont
et al., 2006).
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Genetics
Genome-wide linkage analysis of family A, showed several
neighbouring markers on chromosome 1p35–p31 with LOD
scores above 3.3 with a maximum of 5.72 for marker
D1S2797 (Table: LOD scores; in Supplementary data). No
other markers yielded LOD scores above 1.8. Segregation
analysis identified a disease haplotype spanning a 19.7cM
region between markers D1S233 and D1S2652, comprising
about 377 known genes, including SLC2A1 encoding the
GLUT1 glucose transporter. PCR sequencing of SLC2A1
revealed a heterozygous missense mutation, p.S95I, in exon
4 due to a T-to-A and a C-to-T transition at two neigh-
bouring nucleotides c.[283T4A;284C4T] (numbering
according to cDNA reference sequence NM_006516.1,
numbering started at A of the translation initiation
codon, ATG). This mutation was identified in 22 of the
39 family members, co-segregated with the disease pheno-
type (Fig. 1) and was not present in 184 unrelated
ethnically matched control individuals. We subsequently
identified different mutations in SLC2A1 in three non-
related nuclear families with comparable phenotypes: a
frameshift mutation (c.654dupC; p.N219QfsX18) in patient
B.01 and missense mutations in patient C.01 (c.418G4A;
p.V140M) and patient D.01 (c.950A4C; p.N317T).
The mutations in B.01 and C.01 were not observed in
their parents nor in healthy control individuals.
The four mutations (p.S95I, p.V140M, p.N219QfsX18 and
p.N317T) were localized in the cytosolic loop connecting
transmembrane segments 2 and 3, in transmembrane
segment 4, in the large cytosolic loop connecting transmem-
brane segments 6 and 7 and in transmembrane segment 8,
respectively (Fig. 2). The frameshift mutation (c.654dupC)
predicts a premature stop codon at position 236 in the
protein sequence, resulting in a truncated protein. Align-
ment of homologue protein sequences of different species
with ClustalW (http://www.ebi.ac.uk/clustalw/) showed that
the serine (position 95), valine (position 140) and asparagine
(position 317) residues are highly conserved (alignments,
see Supplementary data), supporting that these mutations
are most likely pathogenic.
Clinical data
Of the 25 individuals (22 of family A, B.01, C.01 and D.01)
carrying a mutation in SLC2A1, 19 had a history of PED
(76%) and 14 of epilepsy (56%); 11 (44%) had a history
of both. Three mutation carriers of family A (II.2, III.4 and
IV.5) were asymptomatic, demonstrating reduced pene-
trance. Two individuals (IV.2; IV.19) who did not carry the
mutation had late-posttraumatic epilepsy and febrile
Fig. 2 The GLUT1protein structure consisting of12 transmembrane domains and intracellular amino- and carboxy-termini
(Mueckler et al., 1985). GLUT1 DS (Klepper and Leiendecker, 2007) and PED/epilepsy mutations are marked on this figure (yellow colored
circles).The PED/epilepsy mutations are boxed.The solid bars indicate the locations of the intron^exon boundaries in the GLUT1 gene.
Splice site mutations are indicated at these solid bars with asterisk.
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did not carry the mutation, suggesting that the mutation
in their child arose de novo (paternity was confirmed with
the analysis of a panel of 31 STR markers located on 15
different chromosomes). Finally, in patient C.03, no muta-
tion was observed. The son of C.03 (paternity was checked),
C.01, had a similar clinical phenotype as his father (PED
without epilepsy) and did carry a mutation in SLC2A1.
PED
Nineteen patients with an SLC2A1 mutation had a history
of PED (Tables 1 and 2). Median age at onset was 8 years
(range: 3–30). In all studied patients involvement of the
legs was present (100%), involving exclusively the legs in
10 (55%), legs more than arms in 6 (33%) and also the face
in two of these 6 (11%). One patient reported that arms and
legs were equally affected, and one that arms were affected
more frequently than legs. The latter patient worked as
a cleaner and reported PED involving the arms precipitated
by exertion of the arms during cleaning. Nine patients
(50%) reported a consistent lateralization, e.g. patient A.III.6
reported onset of the movement disorder always in the left
leg. Nine patients (50%) reported involuntary movements
suggestive of choreoathetosis alone, three (17%) of dystonia
and six of both (33%). The patients described the choreoa-
thetosis as uncontrollable rapid movements, and the
dystonia as stiffening and cramps. PED made walking
impossible, and caused falls in some of the patients. Some
patients were able to stand despite the PED, or walk with
difficulty, but most patients had to sit down until the
movements subsided. Median duration of the PED was
15min (range: 51min to 3h). Precipitating factors were
exertion (n=16, 89%), particularly prolonged brisk walking,
stress (n=7, 39%), starvation (n=5, 28%) and sleep depri-
vation (n=1, 6%). Alleviating factors were eating, preferably
glucose or sugar (n=6, 33%), and rest (n=7, 39%). Patient
A.III.19 remained symptom-free for several years by avoid-
ing long walks. Patient A.III.8 remained symptom-free for
Table 1 Clinical data, EEG, MRI of the brain, serum and CSF glucose concentration
Id G Age
(yr)
E PED EEG MRI PET SG
(mg/dl)
CSF G
(mg/dl)
Ratio CSF G/SG
(Nl40.60)
AED ever
used
A.II.2 F 70 / / / / / / / /
A.III.4 F 57 / / / / / / / /
A.III.6 M 53 + + Nl Nl Y 86 47 0.55 PB, PHT, LTG, LEV, CLB
A.III.8 M 50  + Nl Nl Y 80 43 0.54 VPA
A.III.16 F 46 + + GS Nl Y 83 41 0.49 VPA,TPM
A.III.17 M 43 + + GSW,GS, PS Nl Y 87 50 0.57 VPA, LEV, CBZ, PHT
A.III.19 F 42  +/ /Y 1 0 5 4 9 0 . 4 7 N
A.III.20 F 34  +G S W N l / / / V P A
A.III.21 F 34 U + S LFr / / / / VPA
A.III.22 M 47 + + / / / / / VPA, PHT
A.III.23 M 46  + N l / / / / C B Z ,L T G ,P H T
A.III.24 M 44 + + GSp, Nl BG Nl Y 86 41 0.48 VPA, PHT, LEV
A.IV.5 M 30  Nl / / / / N
A.IV.9 F 30 + + GSW,GSp, Nl BG Nl Y 85 41 0.48 VPA, CBZ,TPM
A.IV.10 M 30 + + GSW, PS, Nl BG Nl / / / VPA, CBZ, PHT
A.IV.11 F 20 +  G S W ,S p ,P S ,N lB G N l Y 6 5 3 4 0 . 5 2 V P A ,E S M ,L T G ,C L B
A.IV.12 F 15 + + GSW, Nl BG Nl Y 78 38 0.49 VPA, LTG
A.IV.18 F 16 +  Nl Nl Y 76 41 0.54 VPA
A.IV.20 F 13  +N l N l Y 7 5 4 0 0 . 5 3 V P A
A.IV.21 M 14  +S L /Y 8 1 4 8 0 . 5 9 V P A
A.V.1 F 7 + + 3Hz GSW,TA during
HV, Nl BG
Nl / / / CBZ,VPA, LTG
A.V.2 F 5 +  Nl / / / / N
B.01
a F2 3 + + S L T N l Y 8 3 4 1 0 . 4 9 V P A , L T G
C.01 M 22  + Nl Nl Y 94 45 0.48 VPA,GBP
C.03 M 47  +/ / 1 0 7 6 4 0 . 6 0 /
D.01 F 22 + + Nl / / / / N
Range 65^1 07 34^64 0.47^0.60
MeanSD 85 11 4 4 7 0.520.04
aOnly patient with abnormal neuronal examination (Mild ataxia, dysarthria, deep tendon reflexes L4R, Babinski sign L).
Id=identification; G=gender; F=female; M=male; yr=years; /=information not available; Nl=normal; L=left; R=right; E=epilepsy;
U=unknown ;+=yes;=no; EEG=electroencephalogram; GSW=generalized spike wave; GS=generalized slowing; PS=polyspikes;
GSp=generalized spikes; S=slowing; Sp=spikes; Fr=frontal;T=temporal; BG=background;TA=typical absence; HV=hyperventilation;
MRI=magnetic resonance imaging; PET=positron emission tomography; SG=serum glucose concentration; CSF G=cerebrospinal fluid
glucose concentration; AED=antiepileptic drug; VPA=valproate; PB=phenobarbital; PHT=phenytoin; LTG=lamotrigine;
LEV=levetiracetam; CLB=clobazam;TPM=topiramate; CBZ=carbamazepine; GBP=gabapentin; ESM=ethosuximide.
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containing snack every 2–3h. C.01 always carried a bottle of
sugar-containing beverage, which reduced the PED episodes.
The PED at its worst occurred on average weekly (ranging
between patients from several attacks daily to yearly) and at
the latest assessment on average yearly (ranging between
patients from weekly to remission of symptoms). Most
patients reported that PED and epilepsy became less severe
when they grew older. Some patients reported autonomic
symptoms, such as sweating, pallor, hyperventilation,
a rising epigastric sensation, psychic symptoms, such as
anxiety and sensory symptoms, such as paraesthesiae, a few
minutes before the onset of the dyskinesias. The treating
neurologists often interpreted the PED as epileptic myo-
clonic jerks as part of juvenile myoclonic epilepsy.
Epilepsy
Fourteen mutation carriers had epilepsy (Tables 1 and 3).
Median age at onset was 2 years (range: 0–19). Seizure
types were absences (n=9, 64%), generalized tonic–clonic
seizures without focal onset (n=7, 50%), complex and
simple partial seizures (n=2, 14%), febrile seizures (n=1,
7%), myoclonic seizures and myoclonic status epilepticus
(n=1, 7%). One patient with partial seizures (A.IV.11)
reported unformed visual hallucinations, a rising epigastric
Table 2 Paroxysmal exercise-induced dyskinesia
Id Age at
onset (yr)
Localization Lateralization Clinical
manifestations
Duration
(min)
Precipitating
factors
Alleviating
factors
Worst
frequency
during lifetime
PED frequency
score
A.III.6 7 Le4A4Fa L4RC A 3 ^ 4 5 E x , S , S T A E , R e 3 3
A.III.8 8 Le4AL 4RC A 2 ^ 1 5 E x E , R e 3 1
A.III.16  20 Le R=L CA 5 S U 4 1
A.III.17 30 Le R = L CA 51E x U 4 4
A.III.19 10 Le R=L D 5 Ex E, Re 3 1
A.III.20 8 A4Le R4L CA, D U Ex U U U
A.III.21 U U U U U U U U U
A.III.22 10 Le R4L CA 3 Ex U 3 2
A.III.23 9 Le L4R CA 30^45 Ex, S U 5 2
A.III.24 8 Le4A4Fa L4R C A ,D 1 5^ 3 0 E x ,S ,S T A E ,R e 4 4
A.IV.9 7 Le4AR 4LC A , D 6 0 E x , S , S T A E 5 4
A.IV.10 3 Le4AR 4L CA 2^180 Ex, STA U 3 1
A.IV.12 6 Le R4L CA, D 2^5 Ex U 5 5
A.IV.20 3 Le R=L CA 30^60 Ex U 2 2
A. IV .2 1 1 3 Le R=L D 30 Ex U 2 2
A. V . 1 6 A=Le R=L CA U S U 2 2
B. 0 1 5 Le R=L CA,D 1 5^30 Ex Re 5 2
C.01 7 Le R=L CA, D 5^30 Ex, S E, Re 4 4
C.03 20 Le R=L CA, D 5^10 Ex R 4 4
D.01 10 Le4A R=L D 1 ^ 5 E x ,S T A ,s l e e p
deprivation
Re 4 4
Id=identification; yr=years; Le=legs; A=arm; Fa=face;U=unknown; L=left; R=right; CA=choreoathetosis; D=dystonia;
S T A=s t a r v a t i o n ;E x=e x e r t i o n ;S=s t r e s s ;E=e a t i n g ;R e=r e s t ;P E Df r e q u e n c ys c o r e :5=d a i l y ;4=w e e k l y ;3=m o n t h l y ;
2=yearly; 1=remission41y ear .
Table 3 Epilepsy
Id Age at
onset (yr)
Seizure
types
Worst seizure
frequency
during
lifetime
Seizure
frequency at
assessment
A.III.6 3 A,GTCS 3 1
A.III.16 0 GTCS 2 1
A.III.17 19 GTCS 3 3
A.III.22 8 A,GTCS 3 3
A.III.24 8 A 4 3
A.IV.09 0 A 5 1
A.IV.10 0 GTCS 2 1
A.IV.11 5 CPS, A, SPS 5 4
A.IV.12 2 CPS,GTCS, SPS 2 1
A.IV.18 2 GTCS 2 1
A.V.1 2 CSE,TA 5 1
A.V.2 1 A, FS 2 1
B.01 2 A 4 1
D.01 19 M, MSE 5 4
Id=ident ificat ion ;y r=years;A=abse nce;GT CS=general ized
tonic^clonic seizure; CPS=complex partial seizure; SPS=simple
partial seizure;TA=typical absence; CSE=convulsive status
epilepticus; FS=febrile seizure; M=myoclonus; MSE=myoclonic
status epilepticus; seizure frequency: 5=daily; 4=weekly;
3=monthly; 2=yearly; 1=remission41y ear .
1836 Brain (2008),131,1 83 1 ^1 844 A.Sulset al.sensation and nausea followed by loss of awareness, staring
and dystonic posturing of the right arm lasting around
one minute. The other patient with partial seizures
(A.IV.12) had simple partial seizures characterized by
visual and auditory hallucinations followed by secondary
generalized tonic–clonic seizures and postictal confusion.
For most of the patients seizure remission was easily
obtained with antiepileptic drug treatment.
Other paroxysmal phenomena
One patient (A.IV.21) had as first manifestation of the
disease an episode of aphasia and right hemiparesis lasting
around 60min at the age of 13 years. One patient (A.III.17)
had an episode of quadriparesis with preserved conscious-
ness lasting around 30min. C.01 frequently had aggressive
outbursts, requiring psychiatric treatment.
Mental status
Most mutation carriers were of average intelligence or had
mild mental retardation. Four patients (A.III.16, A.IV.10,
A.IV.11 and A.IV.12) underwent formal neuropsychological
testing and had a median IQ of 65 (range: 45–79). The
patient with an IQ of 45 (A.III.16) was the only family
member living in a sheltered home. No difference was
observed between the intelligence level of epilepsy patients
and pure PED patients.
EEG
EEG studies were performed in 21 mutation carriers of
families A–D. The EEGs were normal (n=9, 43%), showed
interictal generalized epileptic discharges on a normal back-
ground (n=6, 29%) (Fig. 3), interictal generalized epileptic
discharges with mild to moderate background slowing
(n=2, 10%), generalized mild background slowing (n=1,
5%) and focal slowing (n=3, 14%). Epileptic discharges
were predominant over anterior brain regions. One child
(A.V.1) had two witnessed typical absences during hyper-
ventilation with 3Hz generalized spike-wave discharges on
EEG with a normal background (Fig. 4, Table 1). Seven
patients underwent video-EEG monitoring, including the
proband of family A (IV.12) as well as patients A.III.17,
A.III.20, A.III.24, A.IV.11, B.01 and C.01). During the video-
EEG recordings, patient A.III.24 had two episodes of parox-
ysmal choreoathetosis lasting around 10 and 20min each,
and involving mainly both legs. The movements were
characterized by sudden kicking and bending movements
of the legs, with twisting and trusting movements of
the pelvis (see video; A.III.24 Ictal SPECT during PED, in
supplementary data). Ictal EEGs did not show epileptic
activity. We recorded a nocturnal generalized tonic–clonic
seizure on video-EEG in patient A.III.17, which started with
a 1s burst of polyspikes on EEG, followed by generalized
slow sharp waves admixed with spikes, which became
gradually obscured by muscle artefacts. In the proband
Fig. 3 The interictal EEG of patient A. III.24 showed high voltage anterior predominant generalized spike-wave complexes on a
normal background.Time base: 30mm/s, sensitivity: see calibration: 200mV/cm, high cut: 30.0Hz, low cut: 0.5Hz.
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during prolonged walking, during which she complained of
pain and shakiness in the left leg, without objective signs and
no ictal EEG changes. We recorded one of the episodes of
B.01 during video-EEG recording, which was precipitated by
prolonged walking. Her gait became slightly broad based, she
stumbled and her legs appeared to stiffen. She was unable to
walk unassisted. She recovered within 10min. C.01 under-
went several prolonged video-EEG recordings that did not
show epileptic activity.
Neurological examination
Neurological examination was normal in all mutation car-
riers, except B.01. Her speech was dysarthric, there was mild
appendicular ataxia and deep tendon reflexes on the left
were brisker than on the right, with Babinski sign on the left.
Serum and CSF glucose studies
After identifying the mutations in GLUT1, 14 mutation
carriers underwent a 4- to 8-h-fasting serum glucose and CSF
glucose concentration study. The median ratio of CSF
glucose/serum glucose concentration was 0.52 (range in our
patients: 0.46–0.59, normal:40.60). Median CSF lactate was
1.23mmol/l (range: 0.87–1.36, normal: 0.60–2.20). Median
CSF protein concentration was 376mg/l (range: 264–664,
normal: 150–450). Also, the one patient without
a demonstrable SLC2A1 mutation (C.03) had a lower than
normal ratio of CSF glucose/serum glucose concentration.
Functional studies
We introduced all three missense mutations into the
cDNA of GLUT1 and expressed WT and mutant
(S95I, V140M, N317T) transporters in Xenopus oocytes.
Glucose uptake was largely reduced for all mutations com-
pared with WT transporters (Fig. 5A). A kinetic analysis
of the uptake experiments in oocytes revealed that all
mutations lead to a decrease of the maximum transport
velocity, Vmax, by at least 3- to410-fold, while we observed
no marked change and definitely no increase of the
Michaelis-Menten constant, Km, for mutant compared
with WT transporters (Fig. 5B and Figure legend).
Western blots suggested an equal production and stability
of the mutant proteins compared with the WT (Fig. 5C).
Immunocytochemistry indicated that all three mutants were
properly inserted in the cell surface membrane, similar
to the WT (Fig. 5D).
As an ionic leak for another GLUT1 mutation inducing
increased
86Rb
+ flux was observed by some of us in a family
in which PED is combined with haemolytic anaemia
(Weber et al., 2008), we also performed
86Rb
+ flux experi-
ments with all three mutations. As expected, we did not
observe a significant difference in
86Rb
+ flux compared with
the WT and water-injected oocytes, indicating that these
mutations do not induce an ionic leak of the GLUT1
transporter. This corresponds well to the fact that the
respective patients did not show signs of haemolytic
anaemia.
Imaging
FDG PET: group-based comparison
The group comparison of patients with co-occurring PED
and epilepsy and controls resulted in a relatively increased
glucose metabolism in the putamen (x, y, z=28, 4, 10;
Fig. 4 During hyperventilation, patient A.V.1had a brief absence with high voltage 3Hz generalized spike wave discharges during 6s
on EEG.Time base: 30mm/s, sensitivity (of original recording): 300mV/cm, high cut: 35.0Hz, low cut: 0.5Hz.
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midtemporal cortex bilaterally (x, y, z=54, 34, 2;
pcluster=0.031; x, y, z=48, 36, 4; pcluster=0.011). There
was also relative hypermetabolism in the right lingual
cortex (x, y, z=24, 82, 2; pcluster=0.004). Glucose
metabolism was relatively decreased in patients compared
with controls bilaterally in thalamus (x, y, z=18, 20, 16;
pcluster50.001; x, y, z=14, 24, 14; pcluster50.001),
anterior cingulate cortex (x, y, z=8, 2, 42; pcluster50.001),
midfrontal and superior frontal cortex (x, y, z=18, 2,
52; pcluster50.001; x, y, z=8, 52, 40; pcluster50.001)
(Fig. 6).
Correlation analysis
No significant correlation between relative FDG uptake
and CSF glucose or CSF/blood glucose ratio was found.
There was also no correlation with age. However, we found
a negative correlation between relative FDG uptake and
the epileptic seizure frequency score at the time of PET
scanning in the midfrontal and cingulate cortex bilat-
erally (x, y, z=28, 20, 56; pcluster50.001; r=0.72).
When a patient suffered from more frequent seizures, the
hypometabolism was more pronounced in this brain region.
There was a positive correlation between relative
FDG uptake and the PED frequency score at time of
PET scanning in the left putamen (x, y, z=32, 6, 6;
pcluster=0.013; r=0.67) and a negative correlation in the
left superior frontal cortex (x, y, z=16, 30, 50;
pcluster=0.001; r=0.71) and left anterior cingulate cortex
(x, y, z=4, 30, 20; pcluster=0.006; r=0.59) extending to
the right side (x, y, z=8, 40, 18). When a patient suffered
from more frequent PEDs, the frontal lobe hypometabolism
was more pronounced, as was the relative hypermetabolism
in the putamen.
Ictal SPECT
Ictal SPECT and interictal FDG PET of patient A.III.24
are shown in Fig. 7. Ictal SPECT showed hyperperfusion in
left putamen and leg motor areas. These regions showed
relative hypermetabolism and hypometabolism, respectively,
on interictal FDG PET. The injected episode of PED started
with dyskinesia in the left leg, but around 30s after tracer
Fig. 5 Functional studies to investigate a change in glucose uptake, protein stability or trafficking by the three point mutations in
Xenopus oocytes. (A) Plotted is the glucose uptake versus 3-O-methyl-D-glucose (OMG) concentration.The uptake was significantly
reduced for all three mutations (shown are representative results recorded from one batch of 310 oocytes for each glucose concentra-
tion, means SEM,
P50.05,
P50.001). (B) Kinetic analysis of glucose uptakes in oocytes according to Lineweaver-Burk.The linear
function 1/V (1/[S]) = 1/Vmax+Km/Vmax
1/[S] was fit to the data points, with [S] being the concentration of OMG,V the uptake velocity in
pmol/oocyte/min obtained for a given [S],Vmax the maximal uptake velocity reflecting the maximal transport capacity of GLUT1and Km
the Michaelis-Menten constant representing the concentration [S] for which the half-maximal uptake velocity (V1/2)i sr e a c h e d .Vmax and
Km were calculated from the y-a n dx-interceptions of the linear fits, with the y-intercept equalling1/Vmax and the x-intercept 1/Km.
The following values were obtained (Vmax is given in pmol/oocyte/min and Km in mM): WT: Vmax=3 1 916, Km =1 91; S95I:Vmax =8 62,
Km=1 11; V140M: Vmax=2611, Km=1 59; N317T:Vmax=6018, Km=1 57. (C) Western blots obtained from oocytes injected
with equal amounts of cRNA showed a similar amount of protein for all mutations and the WT, but no respective band for oocytes
injected with H2O as a negative control; a-tubulin was used as a loading control. (D) Immunocytochemical analysis of injected oocytes
using an anti-GLUT1antibody revealed similar stainings of the surface membranes for all four clones.
Mutated GLUTI causes PED and epilepsy Brain (2008),131,1 83 1 ^1 844 1 839Fig. 6 SPM T-map of the analysis of patients versus controls.Relative hypermetabolism in the patient group compared with controls
is indicated in yellow/red, hypometabolism in blue/green. Results are projected on an average spatially normalized in-houseT1 image
ofhealth ycont rols.R=ri ght;L=left.
Fig. 7 Subtraction ictal SPECT coregistered to MRI (SISCOM) (1, 3) during an episode of PED and interictal FDG PET (2, 4) in
patient A.III.24.Top row: coronal images, bottom row: axial images.The episode of PED lasted in total around17min, and was
interrupted by brief moments of no abnormal movements.The dyskinesia mainly involved the legs, left more than right and pelvis (see
video; A.III.24 Ictal SPECT during PED, in supplementary data).The injection was given around three minutes after onset.The SISCOM
(threshold:+2 SD) showed an area of hyperperfusion in the left putamen (blue cross in1), which coincided with interictal putaminal
hypermetabolism (blue cross in 2).Thelargest andmosthyperintensehyperperfusion cluster wasin therightprimarymotor area of theleg
(blue cross in 3), which coincided with an area of hypometabolism in the interictal FDG PET (blue cross in 4). All images are coregistered.
Hyperperfusion clusters are projected on the patient’s MPRAGE images. R=right; L=left.
1840 Brain (2008),131,1 83 1 ^ 1 844 A.S ulset al.injection, the abnormal movement involved both legs,
right more than left (see video; A.III.24 Ictal SPECT during
PED, in supplementary data).
Therapy
Carbohydrate-rich diet
Because sugar and food intake was reported as an alleviat-
ing factor in our families, we started patients A.III.17,
A.III.24, A.IV.11 and A.IV.12 on a carbohydrate-rich diet,
with additional frequent carbohydrate-containing snacks at
regular intervals (every 3–4h). There was no improvement,
and patient A.III.24 reported that frequency and intensity
of PED attacks had worsened.
Ketogenic diet
Since a ketogenic diet is reportedly effective in GLUT1 DS
(De Vivo et al., 1991; Leary et al., 2003; Klepper et al.,
2004), this was initiated in patients A.III.17, A.IV.11 and
A.IV.12. The diet consisted of a strict 3:1 proportion of fat
[3] to protein and carbohydrates [1], fat being supplied in
the form of medium-chain triglyceride mix (Liquigen,
from SHS Nutricia, Liverpool, UK; http://www.shs-nutri
tion.com/shs-product/liquigen). In addition, all patients
received L-carnitine (50mg/kg) and all necessary vitamin
and trace element supplements. The establishment and
follow-up of ketosis was checked twice daily with urine dip
sticks. Patient A.IV.12, who demonstrated 4–5 episodes
daily of PED (cramping of the left leg, inability to walk
450–100m without pausing or dystonia) before starting on
the diet, showed immediate (same day) response when
reaching ketosis. She had complete resolution of PED and
was able to walk and even run long distances for the first
time in her life. As soon as ketosis was lost, e.g. due to diet
non-compliance, symptoms recurred. Patients A.III.17 and
A.IV.11 have been free of epileptic seizures, since the start
of the ketogenic diet (now 2 months—previous frequency
of seizures once weekly in patient A.IV.11 and once
monthly in patient A.III.17). None of the other 21 muta-
tion carriers of family A were willing to start a ketogenic
diet, because in their opinion the advantages did not out-
weigh the disadvantages of the disease and diet itself.
Discussion
Genetics and molecular pathophysiology
of PED and epilepsy
Our study indicates that both PED without epilepsy and
co-occurrence of PED with epilepsy can be caused by
mutations in SLC2A1, which encodes GLUT1, the main
transporter for D-glucose across the BBB. To date, we have
screened four PED families with or without epilepsy and
detected novel SLC2A1/GLUT1 mutations (three missense
and one frameshift) in all of them. In a parallel investi-
gation, Weber and colleagues screened another five PED
families and identified GLUT1 mutations in three of them
(Weber et al., 2008). Both studies suggest that mutations
in GLUT1 may be the most common cause in this condi-
tion. While our identified frameshift mutation predicts
a complete loss of function and haploinsufficiency, the
functional investigations in oocytes showed that all three
missense mutations also lead to a marked reduction of
glucose uptake. The mutations affect the intrinsic ability
of GLUT1 to transport glucose across the cell membrane by
reducing the maximum transport velocity, Vmax, whereas
Km, protein stability and insertion in the surface membrane
did not show major alterations. Hence, attacks of PED can
be caused by a reduced glucose transport across the BBB,
possibly when the energy demand of the brain overcomes
its supply after prolonged periods of exercise.
Clinical aspects, differentiation from
classical GLUT1-DS and genotype^phenotype
correlations
The characteristic clinical features in our patients were PED
and epilepsy. PED consisted of choreoathetosis and dystonia
affecting mainly the legs and was typically precipitated by
prolonged exertion. Epileptic seizures in these patients
appeared mainly as primary generalized, namely as general-
ized tonic–clonic or absences, with a much earlier onset than
classical absence seizures. One patient had myoclonic seizures
and two patients also had partial seizures. Interestingly, the
choreoathetotic PEDs were often misdiagnosed as epileptic
myoclonic seizures as part of juvenile myoclonic epilepsy.
The young age at onset of the epilepsy around 2 years in
combination with a family history of epilepsy and PED are
important clinical clues to suggest the correct diagnosis of this
treatable disease. We conclude that childhood-onset intract-
able exercise-induced dyskinesias, sometimes with co-occur-
ring early-onset generalized epileptic seizures, normal
neurological examination and MRI and a moderately low
CSF glucose concentration are the key features of this
recognizable clinical entity caused by GLUT1 mutations.
Heterozygous mutations in SLC2A1 are also known to
cause a rare, severe syndrome first described by De Vivo
and colleagues in isolated patients, the GLUT1 DS
(OMIM #606777) (De Vivo et al., 1991; Klepper and
Leiendecker, 2007). Most were demonstrated to be total
loss-of-function mutations while other mutations caused a
significant decrease in transport activity (Klepper et al.,
2001a; Iserovich et al., 2002), as observed for our muta-
tions. It is characterized by intractable infantile epileptic
seizures, acquired microcephaly, hypotonia, ataxia, spasti-
city, developmental delay and a persistent reduced CSF/
serum glucose concentration ratio. Exercise-induced dyski-
nesias, normal interictal neurological examination (except
one, B.01), the absence of microcephaly, a different non-
nutrition-dependent form of generalized epilepsy and the
later age at onset differentiate our patients from patients
with classical GLUT1 DS. Other important differences
between our patients and the classical GLUT1 DS patients
Mutated GLUTI causes PED and epilepsy Brain (2008),131, 1831^1844 1841were the less pronounced decrease in fasting CSF glucose
to serum glucose concentration ratio (severe GLUT1 DS:
median 0.33; PED and epilepsy: median 0.52 and normal:
40.60) and apparent improvement in symptomatology over
time in our large family A. Most patients with classical
GLUT1 DS tended to be so severely affected that they were
not able to live independently, to marry and have children,
and hence transmit the disease.
Some patients with an atypical clinical presentation and
GLUT1 mutations were reported in the literature: three
without infantile seizures, one with choreoathetosis and one
with a prominent movement disorder (Overweg-Plandsoen
et al., 2003; Wang et al., 2005; Friedman et al., 2006). In the
latter two patients, the movement disorder was character-
ized by childhood-onset paroxysmal episodes of blinking
and abnormal head and eye movements without definite
seizures in one patient and by intermittent facial and hand
dystonia and mild choreatiform movements of the legs at
rest in the other patient (Wang et al., 2005; Friedman et al.,
2006). Also, three nuclear families with GLUT1 DS were
reported to date, in which the phenotype between family
members varied from intractable epileptic seizures with
moderate mental retardation to controllable epileptic
seizures with mild mental retardation (Brockmann et al.,
2001; Ho et al., 2001; Klepper et al., 2001b). These milder
variants of GLUT1 DS, also proposed by Wang and
colleagues (Wang et al., 2005), have not been well docu-
mented, but in none of all GLUT1 DS patients described in
the literature so far, the complex movement disorder has
ever been described as exercise-induced dyskinesias with
periods lasting from less than a minute to several hours.
Also generalized forms of epilepsy as observed in our
patients have not been described (Klepper and Leiendecker,
2007). These patients can thus be clearly differentiated from
PED with epilepsy described here.
Although missense mutations in the cytosolic loop
connecting transmembrane segments 2 and 3, in trans-
membrane segment 4 and in transmembrane segment 8
have been described in GLUT1 DS patients, the specific
amino acid residues mutated in our patients have not been
related to the pathophysiology of classical or atypical
GLUT1 DS (Fig. 2). It appears that complete loss-of-
function mutations rather cause classical GLUT1 DS, but
other genetic or environmental factors have to play an
important role in the expression of the clinical phenotype
as well, since we also identified a loss-of-function mutation
in one of our PED patients (B.01) and since we could not
find an obvious difference in the uptake studies to the
published point mutations causing classical GLUT1 DS
(Brockmann et al., 2001; Klepper et al., 2001a, 2005; Wang
et al., 2003; Wong et al., 2007). However, the S95I mutant
yielded the mildest phenotype with cases of non-penetrance
(A.II.2, A.III.4 and A.IV.5; who all passed the range of onset
age for PED and epilepsy of this family) and also had the
mildest deficit in glucose transport in vitro. As described for
classical and atypical GLUT1 DS, no clear correlation was
observed between the CSF glucose concentration and the
type of mutation in our study.
Finally, in one patient (C.03) we did not observe an
SLC2A1 mutation despite his clinical phenotype and mildly
reduced CSF/serum glucose ratio. However, this patient has
an affected son (C.01) with an SLC2A1 mutation that could
be explained by a mosaicism.
Functional imaging and systemic
pathophysiology of PED and epilepsy
Relative FDG uptake in our patients with PED and epilepsy
was increased in the putamen, midtemporal cortex bilate-
rally and right lingual brain area, and decreased bilaterally
in thalamus, anterior cingulate cortex, midfrontal and
superior frontal cortex, when compared with a cohort of
matched controls. These findings are principally compar-
able with the ‘metabolic footprint of GLUT1DS on the
brain’ described by Pascual and colleagues (2002). However,
a detailed comparison with this previous study, is difficult
since Pascual and colleagues used visual analysis of indi-
vidual PET scans and provided single PET sections of
14 patients without indication of scaling, whereas we
performed a more objective voxel-based statistical analysis
of grouped data in comparison to normal controls.
Our method allowed us to perform exploratory correla-
tion studies enabling new hypotheses. We found a positive
correlation between relative FDG uptake and the PED fre-
quency score in the left putamen and a negative correlation
in the left superior frontal cortex and bilateral anterior
cingulate cortex. In addition, the ictal SPECT analysis
revealed hyperperfusion in the same regions during an
episode of PED. These findings suggest that disordered
glucose metabolism in the corticostriate pathways plays a
role in the pathophysiology of PED. Furthermore, we found
a negative correlation between seizure frequency and
relative glucose uptake in the midfrontal and cingulate
cortex bilaterally. These observations implicate a disordered
glucose metabolism in the frontal lobes in the pathophys-
iology of the epileptic seizures in our patients, which is
consistent with our EEG findings of generalized epileptic
discharges with anterior predominance. It should be
pointed out that both Pascual’s and our study used non-
quantitative, radioactivity distribution and not quantitative,
regional cerebral glucose utilization (rCMRglc) PET data.
This method allowed us to study the pattern of relative
FDG uptake (Signorini et al., 1999), but not global cerebral
changes, which may be present in persons with GLUT1
mutations. This is a shortcoming of the present study,
which warrants further investigation.
Tre atment
PED and epilepsy is associated with a low CSF glucose
concentration in the presence of normoglycaemia. Although
several family members reported that glucose and sugar
alleviated symptoms, carbohydrate-rich diets have been
1842 Brain (2008),131, 1831^1844 A. Suls et al.reported to be unsuccessful in classical GLUT1 DS (Wang
et al., 2005). A ketogenic diet (high fat, low carbohydrate)
has been effective in patients with classical GLUT1 DS for
management of intractable seizures and complex motor
disorders, but had little effect on the cognitive impairment
(De Vivo et al., 1991; Leary et al., 2003; Klepper et al.,
2004). Ketone bodies derived from fatty acid oxidation in
the liver can penetrate the BBB by means of another
transporter and can thus provide an alternative fuel for
brain metabolism. Our initial experiences with the keto-
genic diet in two adolescents and one adult are encourag-
ing. Since the ketogenic diet has been used mainly in
children and long-term effects in adults have not been
established, careful follow-up of the patients is indicated.
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